封面
市场调查报告书
商品编码
1541300

2024-2032 年按药物、药物类型、给药途径、配销通路和地区分類的多发性硬化症治疗市场报告

Multiple Sclerosis Therapies Market Report by Drug, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032

出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年,全球多发性硬化症治疗市场规模达到269亿美元。

多发性硬化症 (MS) 是一种慢性发炎性免疫介导疾病,可导致脊髓和大脑神经细胞脱髓鞘、轴突横断和神经退化。一些常用的疗法包括注射、口服和输注药物、肌肉鬆弛剂、抗忧郁药物和物理疗法。注射药物,如干扰素-β和醋酸格拉默,可在皮下或肌肉内注射;口服药物包括富马酸二甲酯、特立氟胺和克拉屈滨;输注治疗包括 Ocrelizumab、Natalizumab 和 Alemtuzumab,均以静脉注射。这些药物有助于控制症状,最大限度地减少復发频率并控制患者的心率和血压。

全球復发缓解型多发性硬化症(RRMS)、原发性进展型多发性硬化症(PPMS)、继发性进展型多发性硬化症(SPMS) 和进行性復发型多发性硬化症(PRMS) 的盛行率不断增加,是推动多发性硬化症成长的关键因素之一市场。此外,老年人口的增加更容易患此类疾病,这也推动了市场的成长。医疗保健提供者广泛使用免疫抑制剂来控制自体免疫攻击并防止多发性硬化症患者復发。此外,各种技术进步,例如用于有效治疗多发性硬化症的创新单株、免疫调节剂、免疫抑制剂和干扰素的开发,也是其他主要的生长诱导因素。除此之外,已开发国家和新兴国家的政府都在发起运动,以提高大众对可用治疗替代方案的认识,这反过来又为市场创造了积极的前景。其他因素,包括广泛的研发(R&D)活动以及医疗保健基础设施的改善,预计将进一步推动市场发展。

本报告回答的关键问题:

  • 迄今为止,全球多发性硬化症治疗市场表现如何,未来几年将如何表现?
  • COVID-19 对全球多发性硬化症治疗市场有何影响?
  • 主要区域市场有哪些?
  • 基于药物的市场区隔是什么?
  • 根据药物类型分類的市场是怎么样的?
  • 根据给药途径,市场的分化为何?
  • 基于配销通路的市场区隔是什么?
  • 产业价值链的各个阶段是什么?
  • 该行业的关键驱动因素和挑战是什么?
  • 全球多发性硬化症治疗市场的结构是什么?
  • 产业竞争程度如何?

目录

第一章:前言

第 2 章:范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章:执行摘要

第 4 章:简介

  • 概述
  • 主要行业趋势

第 5 章:全球多发性硬化症治疗市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章:市场区隔:依药品分类

  • 免疫调节剂
    • 市场趋势
    • 主要类型
      • 科帕松
      • Avonex/Plegridy
      • 吉尔内亚
      • 蒂萨布里
      • 倍他龙/Extavia
      • 特西菲德拉
      • 雷比夫
      • 安皮拉
    • 市场预测
  • 免疫抑制剂
    • 市场趋势
    • 主要类型
      • 奥巴焦
      • 莱姆特拉达
      • 奥瑞珠单抗
      • 津布里塔
    • 市场预测

第 7 章:市场区隔:按药物类型

  • 生物药
    • 市场趋势
    • 市场预测
  • 小分子药物
    • 市场趋势
    • 市场预测

第 8 章:市场区隔:依管理途径

  • 口服
    • 市场趋势
    • 市场预测
  • 可注射
    • 市场趋势
    • 市场预测
  • 静脉
    • 市场趋势
    • 市场预测

第 9 章:市场区隔:按配销通路

  • 医院药房
    • 市场趋势
    • 市场预测
  • 零售药局
    • 市场趋势
    • 市场预测
  • 网路药局
    • 市场趋势
    • 市场预测

第 10 章:市场区隔:按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分:按国家/地区
    • 市场预测

第 11 章:SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章:价值链分析

第 13 章:波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章:价格分析

第15章:竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbvie Inc.
    • Bayer Aktiengesellschaft
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG (Roche Holding AG)
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Novartis AG
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112024A2571

The global multiple sclerosis therapies market size reached US$ 26.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 37.8 Billion by 2032, exhibiting a growth rate (CAGR) of 3.7% during 2024-2032.

Multiple sclerosis (MS) refers to a chronic and inflammatory immune-mediated condition that can cause demyelination, axonal transection and neurodegeneration of the nerve cells in the spinal cord and brain. Some of the commonly used therapies include the administration of injectable, oral and infused medicines, muscle relaxants, antidepressants and physical therapy. The injectable medication, such as Interferon-beta and Glatiramer acetate, are administered under the skin or into the muscle; oral medications include Dimethyl fumarate, Teriflunomide and Cladribine; and infusion treatments include Ocrelizumab, Natalizumab and Alemtuzumab, which are administered intravenously. These medicines aid in managing the symptoms to minimize the frequency of the relapses and control the heart rate and blood pressure of the patient.

The increasing prevalence of relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) across the globe, is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Healthcare providers are widely using immunosuppressants that control autoimmune attacks and prevent relapses among patients suffering from MS. Additionally, various technological advancements, such as the development of innovative monoclonal bodies, immunomodulators, immunosuppressants and interferons for the effective treatment of MS, are acting as other major growth-inducing factors. Apart from this, governments of both the developed and emerging countries are launching campaigns to increase awareness regarding the available treatment alternatives among the masses, which, in turn, is creating a positive outlook for the market. Other factors, including extensive research and development (R&D) activities, along with the improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple sclerosis therapies market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug, drug type, route of administration and distribution channel.

Breakup by Drug:

Immunomodulators

Copaxone

Avonex/Plegridy

Gilneya

Tysabri

Betaseron/Extavia

Tecifidera

Rebif

Ampyra

Immunosuppressants

Aubagio

Lemtrada

Ocrelizumab

Zinbryta

Breakup by Drug Type:

Biologic Drugs

Small Molecule Drugs

Breakup by Route of Administration:

Oral

Injectable

Intravenous

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global multiple sclerosis therapies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global multiple sclerosis therapies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global multiple sclerosis therapies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Multiple Sclerosis Therapies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug

  • 6.1 Immunomodulators
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Copaxone
      • 6.1.2.2 Avonex/Plegridy
      • 6.1.2.3 Gilneya
      • 6.1.2.4 Tysabri
      • 6.1.2.5 Betaseron/Extavia
      • 6.1.2.6 Tecifidera
      • 6.1.2.7 Rebif
      • 6.1.2.8 Ampyra
    • 6.1.3 Market Forecast
  • 6.2 Immunosuppressants
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Aubagio
      • 6.2.2.2 Lemtrada
      • 6.2.2.3 Ocrelizumab
      • 6.2.2.4 Zinbryta
    • 6.2.3 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Biologic Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Small Molecule Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Intravenous
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbvie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bayer Aktiengesellschaft
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Biogen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Bristol-Myers Squibb Company
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 SWOT Analysis
    • 15.3.6 GlaxoSmithKline Plc
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck & Co. Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Sanofi S.A.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Multiple Sclerosis Therapies Market: Major Drivers and Challenges
  • Figure 2: Global: Multiple Sclerosis Therapies Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Multiple Sclerosis Therapies Market: Breakup by Drug (in %), 2023
  • Figure 4: Global: Multiple Sclerosis Therapies Market: Breakup by Drug Type (in %), 2023
  • Figure 5: Global: Multiple Sclerosis Therapies Market: Breakup by Route of Administration (in %), 2023
  • Figure 6: Global: Multiple Sclerosis Therapies Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Multiple Sclerosis Therapies Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Multiple Sclerosis Therapies (Immunomodulators) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Multiple Sclerosis Therapies (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Multiple Sclerosis Therapies (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Multiple Sclerosis Therapies (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Multiple Sclerosis Therapies (Injectable) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Multiple Sclerosis Therapies (Injectable) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Multiple Sclerosis Therapies (Intravenous) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Multiple Sclerosis Therapies (Intravenous) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: North America: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: North America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: United States: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: United States: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Canada: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Canada: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Asia Pacific: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Asia Pacific: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: China: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: China: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Japan: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Japan: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: India: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: India: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: South Korea: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: South Korea: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Australia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Australia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Indonesia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Indonesia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Europe: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Europe: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Germany: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Germany: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: France: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: France: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: United Kingdom: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: United Kingdom: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Italy: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Italy: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Spain: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Spain: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Russia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Russia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Latin America: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Latin America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Brazil: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Brazil: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Mexico: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Mexico: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Middle East and Africa: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Middle East and Africa: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Multiple Sclerosis Therapies Industry: SWOT Analysis
  • Figure 78: Global: Multiple Sclerosis Therapies Industry: Value Chain Analysis
  • Figure 79: Global: Multiple Sclerosis Therapies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Multiple Sclerosis Therapies Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug (in Million US$), 2024-2032
  • Table 3: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 4: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 5: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Multiple Sclerosis Therapies Market Structure
  • Table 8: Global: Multiple Sclerosis Therapies Market: Key Player